Granules India Stock

Granules India EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Granules India (GRANULES.NS) as of Aug 23, 2026 is 9.50 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 8.60 B INR — a change of 10.47% (higher).

EBITDA

9.50 BINR

YoY

10.47%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Granules India is 2026 9.50 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Granules India was 2025 8.60 B INR. It decreases by 10.47% higher compared to the previous year.

The Granules India EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
2.79 B INR
Jan 1, 2019
3.84 B INR
Jan 1, 2020
5.59 B INR
Jan 1, 2021
8.65 B INR
Jan 1, 2022
7.34 B INR
Jan 1, 2023
9.22 B INR
Jan 1, 2024
8.60 B INR
Jan 1, 2025
9.50 B INR
The Granules India EBITDA history
YEAREBITDAYoY
9.50 BINR+10.47%
8.60 BINR-6.72%
9.22 BINR+25.72%
7.34 BINR-15.16%
8.65 BINR+54.75%
5.59 BINR+45.34%
3.84 BINR+38.03%
2.79 BINR-8.51%
3.04 BINR+10.29%
2.76 BINR+32.18%
2.09 BINR+31.65%
1.59 BINR
Access this data via the Eulerpool API

Granules India Stock analysis

What does Granules India do? Granules India Ltd is a registered company in Hyderabad, India, specializing in the manufacturing of pharmaceutical active ingredients and formulations, product development, biotechnology research, and diagnostics. The company was established in 1984 and has become one of the leading suppliers of pharmaceutical active ingredients. The origins of Granules India Ltd began as a small company with only a few employees. In 1991, the company started production of Allantoin, a cosmetic active ingredient. Over the years, the company steadily grew and expanded its production capacities. In 1995, Granules India Ltd began manufacturing pharmaceutical active ingredients as part of its business. In the late 90s, the company expanded into other countries to distribute its products worldwide. Today, the main markets for Granules India Ltd are India, North America, Europe, and Asia. The company also has distribution offices in the USA, Europe, and Asia. Granules India Ltd has divided its business model into three main sectors: 1. Pharmaceutical Active Ingredients (APIs) - Granules India Ltd specializes in the manufacturing of pharmaceutical active ingredients used in drug production. The company produces a wide range of APIs, including Paracetamol, Ibuprofen, Metformin, and more. 2. Formulations - Granules India Ltd also produces various pharmaceutical formulations such as tablets, capsules, suspensions, and more. The company is able to develop and manufacture customized formulations according to customer requirements. 3. Biologics - In recent years, the company has also invested in biotechnology research, particularly in the development and manufacturing processes of biologics such as antibody drugs. The field of diagnostics is also covered. Granules India Ltd has established a strong position as a manufacturer of pharmaceutical active ingredients in recent years. The company supplies many of the major pharmaceutical companies worldwide. It has six production facilities in India that manufacture pharmaceutical active ingredients and formulations. The company also supplies to other manufacturers to support their production processes. In terms of products, Granules India Ltd offers a wide range of pharmaceutical active ingredients and formulations, all manufactured to the highest quality and in compliance with international standards. Some of the company's most well-known products are Paracetamol, Ibuprofen, Metformin, and Tramadol, used in pain management. The wide range of formulations includes tablets, capsules, suspensions, and more, used in various therapy areas such as cardiology, oncology, neurology, and infectious diseases. Overall, Granules India Ltd has achieved a leading position in the market for pharmaceutical active ingredients and formulations. The company has invested in research and development in recent years to expand its product range and provide customized solutions. Granules India Ltd remains committed to meeting the high standards in the pharmaceutical industry and developing innovative products to meet the needs of its customers. Granules India is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Granules India stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Granules India is 9.50 B INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Granules India changed from 8.60 B INR to 9.50 B INR, representing a 10.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Granules India since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Granules India historically and in real time.

Access this data via the Eulerpool API

Income Statement — Granules India

All Key Metrics — Granules India